Twitter | Search | |
Search Refresh
Stephanie Lee, MD Dec 11
My first tweet ever, to start sharing what it’s like to be the 2020 ASH President. Thanks for the kind words! Tweets will start in the New Year.
Reply Retweet Like
Rafael Fonseca MD Dec 14
WHAT IS THE RISK CLASSIFICATION OF THE t(11;14) in MM? This has been a long-debated question and probably asked in the wrong way. I have always had a special interest in the t(11;14) and want to tell a story and how it relates to venetoclax. 1/x
Reply Retweet Like
Andy Biotech Dec 16
Anti-BCMA ADC pivotal data out 31% ORR 3% CR 27% Gr3/4 keratopathy Very hard to see how this risk/benefit profile can be competitive in the super crowded BCMA space. No wonder this data couldn't get into LBA.
Reply Retweet Like
Nina Shah Dec 10
Final display of selfies. So many that I had to do collages. If you took a pic with me you’re probably in here. Back in SF (finally) and looking forward to seeing everyone next year. Happy holidays to all
Reply Retweet Like
Genentech Dec 17
Apoptosis, or cellular self-destruction, is how our body rids itself of cells that are damaged, infected or mutated. Read "Turning a New Leaf" to learn how a family of proteins can trigger cancer cells to self-destruct.
Reply Retweet Like
ASTCT Dec 19
The Committee on Cellular Therapy's Writing Group from the 2019 ASTCT CAR-T Cell Therapy Management Consensus Conference held a working group meeting at . The group met to continue to work on and refine their toxicity management guidelines from the 2019 conference.
Reply Retweet Like
Mehdi Hamadani Dec 11
Dealing with post ASH clinic and mail box
Reply Retweet Like
National Cancer Institute Jan 14
Immunotherapy drug improves outcomes for some children with relapsed leukemia
Reply Retweet Like
Agios Dec 11
Our pushes us to do more for patients. The work continues as we strive for the other side of possible. Thanks for another insightful meeting!
Reply Retweet Like
Katherine King MDPhD Dec 10
Another great ⁦⁩ reunion at , now with a growing number of F2s! I love how this group provides each other career-long support! ⁦
Reply Retweet Like
Michelle Lavin Dec 11
Heartwarming welcome back home from to Ireland from the lovely childrens choir in T2 Jingle bells in Irish (Bualadh bos as Gaeilge) Great to be home, cant help getting in Christmas spirit seeing this after a long overnight flight ☘🎅
Reply Retweet Like
Jacob Shreve Dec 16
I had the pleasure of presenting our machine learning AML prognostic model at last week! This sort of research is why I came to , and made possible by the tutelage of .
Reply Retweet Like
MDedge Hematology & Oncology Jan 30
Podcast: Blood & Cancer takes you behind the podium for an in-depth look at the latest developments in hematology. Plus, talks about gratitude and surviving cancer. . , ,
Reply Retweet Like
Raul Cordoba, MD, PhD Dec 21
How should we use geriatric assessment to guide treatment decisions for elderly patients with DLBCL?
Reply Retweet Like
Michael Makris Jan 23
Patients with antiphospholipid syndrome () are more likely to develop catastrophic APS if they have mutations in the complement genes. This was my favourite presentation at .
Reply Retweet Like
Abby Statler Feb 25
Winston was so excited to meet - he fist pumped 👊🏻 for the first time 😀 ! After all that practicing for , I’m pretty confident Winston’s first words will be hematologic malignancy 😂
Reply Retweet Like
Michael O'Dwyer Jan 4
BioCentury - SIGLECs go from homing beacons to next-generation checkpoints. Fits in with our strategy of deleting on cells for adoptive as presented
Reply Retweet Like
Oncology Tube Mar 25
Multiple Myeloma Disparities : Ajay K. Nooka, MD of discusses multiple myeloma disparities.
Reply Retweet Like
Julie Feldstein,M.D., FCAP Dec 19
4262 Generation of a New Prognostic Index for Chronic Myelomonocytic Leukemia (CMML) Based on Peripheral Blood Assessment s/p
Reply Retweet Like
Michael Makris Jan 6
Important article for anyone interested in gene therapy and missed the Sabatino presentation at . Anybody opting for gene therapy should read this. Long term safety of AAV gene therapy is unknown.
Reply Retweet Like